Published On: Wed, Oct 19th, 2016

Recently Changed Price Targets On Keryx Biopharmaceuticals, Inc. (KERX)


A number of investment brokers have recently updated their price targets on shares of Keryx Biopharmaceuticals, Inc. (KERX).

Most recent broker ratings

10/17/2016 – Keryx Biopharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 7 price target on the stock.

08/02/2016 – Keryx Biopharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Cowen.

08/02/2016 – Keryx Biopharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Raymond James. They now have a USD 7 price target on the stock.

08/02/2016 – Keryx Biopharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 9 price target on the stock.

08/02/2016 – Keryx Biopharmaceuticals, Inc. was downgraded to “hold” by analysts at Stifel Nicolaus.

08/02/2016 – Keryx Biopharmaceuticals, Inc. was downgraded to “hold” by analysts at Brean Capital.

08/01/2016 – Keryx Biopharmaceuticals, Inc. was downgraded to “hold” by analysts at Maxim Group. They now have a USD 9 price target on the stock.

03/29/2016 – Keryx Biopharmaceuticals, Inc. had its “sell” rating reiterated by analysts at BTIG Research. They now have a USD 2.5 price target on the stock.

02/26/2016 – Keryx Biopharmaceuticals, Inc. was downgraded to “neutral” by analysts at JP Morgan.

10/05/2015 – Keryx Biopharmaceuticals, Inc. was upgraded to “equal-weight” by analysts at Morgan Stanley. They now have a USD 3 price target on the stock.

09/24/2015 – Keryx Biopharmaceuticals, Inc. had its “sell” rating reiterated by analysts at Citigroup. They now have a USD 1.5 price target on the stock.

08/10/2015 – Keryx Biopharmaceuticals, Inc. was downgraded to “neutral” by analysts at Roth Capital. They now have a USD 6 price target on the stock.

08/06/2015 – Keryx Biopharmaceuticals, Inc. had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 25 price target on the stock.

05/06/2015 – Keryx Biopharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Mizuho. They now have a USD 21 price target on the stock.

05/05/2015 – Keryx Biopharmaceuticals, Inc. was upgraded to “hold” by analysts at Zacks.

The share price of Keryx Biopharmaceuticals, Inc. (KERX) was down -2.59% during the last trading session, with a day high of 4.74. 2286525 shares were traded on Keryx Biopharmaceuticals, Inc.’s last session.

The stock’s 50 day moving average is 4.87 and its 200 day moving average is 5.47. The stock’s market capitalization is 477.59M. Keryx Biopharmaceuticals, Inc. has a 52-week low of 2.80 and a 52-week high of 7.80.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Company operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough. The Company focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia.